Sorbonne University

Median Technologies to Participate and Speak at the 2024 European Congress of Radiology (ECR), February 28 – March 3, Vienna, Austria

Retrieved on: 
Monday, February 26, 2024

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.
  • Philippe Grenier, Thoracic Radiologist and Head of the Artificial Intelligence project, Foch Hospital, Saint Cloud, France and Pr.
  • The European Congress of Radiology (ECR) organized by the European Society of Radiology (ESR) is the premier European event in radiology and the second largest in the world.
  • The congress conveys more than 20,000 with a split of more than 10,000 professional delegates (radiologists, technologists etc.

Club Med, the Pioneer of the All-Inclusive Concept, Announces New Renovations, Wellness Fusion Program Expansion, Generative AI Integration, CSR Commitments and Limited-Time Winter Sale

Retrieved on: 
Wednesday, February 14, 2024

The Wellness Fusion program is now available across seven North America resorts including: Club Med Michès Playa Esmeralda, Club Med Punta Cana, Club Med Québec, Club Med Ixtapa Pacific, Club Med Cancún, Club Med Columbus and Club Med Turkoise.

Key Points: 
  • The Wellness Fusion program is now available across seven North America resorts including: Club Med Michès Playa Esmeralda, Club Med Punta Cana, Club Med Québec, Club Med Ixtapa Pacific, Club Med Cancún, Club Med Columbus and Club Med Turkoise.
  • Club Med is continuing to explore new types of AI to improve customer service, like Claude AI from Anthropic.
  • Environmental Partnerships: Turtle monitoring and protection program in Club Med Ixtapa Pacific, Club Med Cancún and Club Med Michès Playa Esmeralda's pioneer program that launched in 2023; Turks and Caicos Reef Fund with interactive workshops on coral reefs at Club Med Turkoise and Club Med Columbus.
  • Additional 10% off on premium rooms with code: 10CLUB
    Resorts: Club Med Punta Cana, Club Med Michès Playa Esmeralda, Club Med Cancún, Club Med Ixtapa Pacific, Club Med Turkoise, Club Med Columbus, Club Med Caravelle, Club Med Buccaneer's Creek

The New Look: Apple TV drama shows how Dior brought optimism to a war-weary world

Retrieved on: 
Wednesday, February 14, 2024

Dior’s haute couture collection remains a historical moment for post-war fashion, and lends its name to Apple’s new ten-part series.

Key Points: 
  • Dior’s haute couture collection remains a historical moment for post-war fashion, and lends its name to Apple’s new ten-part series.
  • The drama explores the state of Parisian couture in the final year of the second world war and the years that followed through the lives of important designers.
  • This includes Dior and his contemporaries Coco Chanel, Pierre Balmain, Cristóbal Balenciaga, Lucien Lelong, Hubert de Givenchy and Pierre Cardin.

French fashion during wartime

  • Once Nazi forces invaded, Paris and its international fashion markets were effectively cut off from the rest of the world.
  • As fashion designers were forced to limit the amount of material they used, unnecessary decorative additions such as ruffles and pockets became expendable.
  • Instead, wartime couturiers turned to embroidery and beading for decoration – trends that continue to characterise haute couture today.

The rival ‘American look’

  • Its biggest rival was the American ready-to-wear apparel industry, an aspect of the story this new series dramatises to great effect.
  • Though the American industry also faced fabric rationing during the second world war, it was not occupied, and the restrictions weren’t as debilitating.

Dior’s beacon of hope

  • Dior’s 1947 Carolle collection, was renamed the “new look” at first viewing by American fashion editor Carmel Snow.
  • Snow claimed it represented the creation of a new femininity – which Dior would later call “the golden age of couture”.
  • Rather, it celebrated the end of the grim years of wartime trauma, misery and lack.


Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Elizabeth Kealy-Morris does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

SCOR supports actuarial science by presenting Actuarial Awards in six countries in 2023

Retrieved on: 
Thursday, December 14, 2023

The SCOR Actuarial Awards are recognized in the insurance and reinsurance industries as a mark of excellence.

Key Points: 
  • The SCOR Actuarial Awards are recognized in the insurance and reinsurance industries as a mark of excellence.
  • The Actuarial Awards in France are supported by the SCOR Corporate Foundation for Science, chaired by André Lévy-Lang.
  • The SCOR Actuarial Awards juries are composed of internationally recognized researchers and insurance, reinsurance and finance professionals.
  • In 2023, SCOR presented Actuarial Awards in six countries: France, Germany, Italy, Spain, Sweden and Switzerland.

Qubit Pharmaceuticals and Sorbonne University achieve a major scientific breakthrough by simulating quantum calculations at more than 40 qubits on conventional computers

Retrieved on: 
Wednesday, December 6, 2023

Qubit Pharmaceuticals introduces its Hyperion-1 emulator, developed in close collaboration with Sorbonne University and capable of running accelerated and accurate quantum algorithms at over 40 qubits.

Key Points: 
  • Qubit Pharmaceuticals introduces its Hyperion-1 emulator, developed in close collaboration with Sorbonne University and capable of running accelerated and accurate quantum algorithms at over 40 qubits.
  • Paris, December 6th, 2023 - Qubit Pharmaceuticals, a deeptech company specializing in the discovery of new drug candidates through molecular simulation and modeling accelerated by hybrid HPC and quantum computing, announces a major scientific breakthrough after achieving quantum computations simulating 40 qubits with its new Hyperion-1 emulator.
  • This achievement reinforces Qubit Pharmaceuticals' ambition to become the industry reference in molecular modeling-based drug discovery.
  • Exceptional performance: Hyperion-1 has demonstrated outstanding performance in high-speed simulations of complex quantum circuits of up to 40 qubits, using moderate computing resources, i.e.

One Biosciences Partners With AP-HP to Launch a Single-cell Research Project on a Rare Kidney Disease

Retrieved on: 
Friday, November 10, 2023

PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.

Key Points: 
  • PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.
  • A condition characterized by a gradual loss of kidney function over time, this particular disease has no viable therapeutic option to date and transplantation is often the only alternative, despite frequent relapses.
  • One Biosciences will leverage the data to identify new therapeutic targets in this rare kidney disease in order to develop precision medicines and biomarkers of a relapse of the disease via its discovery platform.
  • This is an important milestone, and I'd like to thank our partners for their commitment," said Hedi Ben Brahim, CEO of One Biosciences.

MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations

Retrieved on: 
Tuesday, December 12, 2023

---

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announced that it will host a virtual KOL (Key Opinion Leader) event on data presented during the 2023 ASH annual meeting including efficacy and safety results for its lead drug candidate, MaaT013, currently in development for acute Graft-versus-Host Disease (aGvHD) and details on MaaT033, developed as an adjuvant therapy to improve patients’ survival following allogeneic hematopoietic stem cell transplantation (allo-HSCT), on Monday, December 18, 2023, at 6:00 pm CET (12:00 pm EST).
  • The event will feature presentations from the Company’s CEO and co-founder, Hervé Affagard as well as the following KOLs:
    Mohamad Mohty, M.D., Ph.D., Professor of Hematology at Sorbonne University, and head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, Paris, France will comment on the positive data on MaaT013 presented for the Early Access Program; and
    Florent Malard, M.D., Ph.D., Professor of Hematology at the Saint-Antoine Hospital and Sorbonne University, Principal investigator of Phase 2b trial evaluating MaaT033 in patients receiving allo-HSCT, will provide detailed information on the ongoing trial.
  • Registration & link to access the event: https://app.livestorm.co/newcap-1/maat-pharma-presentation?type=detailed
    A replay will be made available on the Company’s website for at least 90 days.

MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023

Retrieved on: 
Monday, December 11, 2023

“It reinforces our approach based on restoring patients’ immune systems through gut microbiome ecosystem therapies.

Key Points: 
  • “It reinforces our approach based on restoring patients’ immune systems through gut microbiome ecosystem therapies.
  • OS was 56% at 6 months and 47% at 12 months with a median follow up of 355 days.
  • A Phase 3 trial is currently ongoing in Europe to confirm these results in ruxolitinib-refractory patients ( NCT04769895 ) with ORR expected in mid-2024.
  • MaaT Pharma also presented its ongoing Phase 2b trial design for MaaT033, its second candidate, at the 2023 ASH Annual Meeting.

MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT

Retrieved on: 
Monday, November 6, 2023

The trial is an international, multi-center, randomized, double-blind, placebo-control study ( NCT05762211 ), which will be conducted in up to 56 clinical investigation sites and is expected to enroll 387 patients.

Key Points: 
  • The trial is an international, multi-center, randomized, double-blind, placebo-control study ( NCT05762211 ), which will be conducted in up to 56 clinical investigation sites and is expected to enroll 387 patients.
  • It is to date the largest randomized controlled trial assessing a microbiome therapy in oncology.
  • “Today marks a significant milestone for us as our second product, MaaT033, enters Phase 2b clinical trials in allo-HSCT.
  • - Secondary endpoints include evaluation of safety and tolerability before and after allo-HSCT, and evaluation of the engraftment of beneficial microbial species from MaaT033.

Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board

Retrieved on: 
Thursday, August 10, 2023

Professor Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine.

Key Points: 
  • Professor Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine.
  • Professor Cornelis received his MD in 2003 and completed his radiology training and his fellowship in 2008 and 2010, respectively, at the University of Bordeaux in France.
  • “The support and endorsement of a global leader such as Professor Cornelis is a vote of confidence and a great honor for the company.
  • Professor Cornelis joins a team of global leaders in their fields that are already serving as members of our SAB,” said Dr. Eyal Morag, Chief Medical Officer of Microbot Medical.